A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

RC108

RC108 in Combination With Furmonertinib

DRUG

Furmonertinib Mesilate Tablets Monotherapy

Furmonertinib

Trial Locations (34)

Unknown

RECRUITING

Beijing Chest Hospital,Capital Medical Unniversity, Beijing

RECRUITING

The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing

RECRUITING

Binzhou Medical University Hospital, Binzhou

RECRUITING

Jilin Cancer Hospital, Changchun

RECRUITING

The Second Xiangya Hospital Of Central South University, Changsha

RECRUITING

Changzhou Cancer Hospital, Changzhou

RECRUITING

Sichuan Cancer Hospital, Chengdu

RECRUITING

West China hospitial of SiChuan University, Chengdu

RECRUITING

Chongqing University Cancer Hospitai, Chongqing

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Ganzhou cancer Hospitial, Ganzhou

RECRUITING

Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Guilin

RECRUITING

The Second Affiliated Hospital of Guilin Medical University, Guilin

RECRUITING

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

Anhui Provincial cancer hospital, Hefei

RECRUITING

The First hospitial of Anhui Medicine University, Hefei

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

The First hospitial of Lanzhou University, Lanzhou

RECRUITING

Linyi People's Hospital, Linyi

RECRUITING

THE FIRST HOSPITAI OF CHINA MEDICAL UNIVERSITY,No. 155, Nanjing North Street, Heping District, Shenyang City, Liaoning Province, Shenyang

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

RECRUITING

Shanxi Cancer Hospital, Taiyuan

RECRUITING

Taizhou hospitial of Zhejiang province, Taizhou

RECRUITING

Tianjin Chest Hospital, Tianjin

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Xiangyang Central Hospital, Xiangyang

RECRUITING

The Second People's Hospital of Yibin City, Yibin

RECRUITING

Yiyang Central Hospital, Yiyang

RECRUITING

Yueyang Central Hospital, Yueyang

RECRUITING

Yunnan Cancer Hospital, Yunnan

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT06962865 - A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | Biotech Hunter | Biotech Hunter